150 related articles for article (PubMed ID: 22128200)
1. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women.
Klipping C; Duijkers I; Remmers A; Faustmann T; Zurth C; Klein S; Schuett B
J Clin Pharmacol; 2012 Nov; 52(11):1704-13. PubMed ID: 22128200
[TBL] [Abstract][Full Text] [Related]
2. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study.
Endrikat J; Parke S; Trummer D; Serrani M; Duijkers I; Klipping C
Contraception; 2013 Feb; 87(2):227-34. PubMed ID: 22995539
[TBL] [Abstract][Full Text] [Related]
3. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.
Endrikat J; Parke S; Trummer D; Schmidt W; Duijkers I; Klipping C
Contraception; 2008 Sep; 78(3):218-25. PubMed ID: 18692612
[TBL] [Abstract][Full Text] [Related]
4. The effect of a single midcycle administration of 0.5 or 2.0 mg dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on pituitary and ovarian function--investigation for the use as a postcoital contraceptive.
Köhler G; Göretzlehner G; Rudolf K; Rüting M; Meissner J; Kunkel S; Schollberg K
Exp Clin Endocrinol; 1984 Dec; 84(3):299-304. PubMed ID: 6441728
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of emergency contraception with gestrinone: a preliminary investigation.
Gao X; Wu E; Chen G
Contraception; 2007 Sep; 76(3):221-7. PubMed ID: 17707720
[TBL] [Abstract][Full Text] [Related]
6. [Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations].
Oettel M; Carol W; Gräser T; Klinger G; Mellinger U; Moore C; Schindler AE; Winkler UH
Zentralbl Gynakol; 1997; 119(12):597-606. PubMed ID: 9483810
[TBL] [Abstract][Full Text] [Related]
7. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
[TBL] [Abstract][Full Text] [Related]
8. Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys.
Sasagawa S; Shimizu Y; Nagaoka T; Tokado H; Imada K; Mizuguchi K
J Endocrinol Invest; 2008 Jul; 31(7):636-41. PubMed ID: 18787383
[TBL] [Abstract][Full Text] [Related]
9. Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats.
Davis BJ; Maronpot RR; Heindel JJ
Toxicol Appl Pharmacol; 1994 Oct; 128(2):216-23. PubMed ID: 7940536
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
Schneider WH; Schmid R; Spona J
Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
[TBL] [Abstract][Full Text] [Related]
11. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid.
Katsuki Y; Sasagawa S; Takano Y; Shibutani Y; Aoki D; Udagawa Y; Nozawa S
Drugs Exp Clin Res; 1997; 23(2):45-62. PubMed ID: 9309380
[TBL] [Abstract][Full Text] [Related]
12. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Spona J; Huber J; Schmidt JB
Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ovulation by a new low-dose monophasic contraceptive containing gestodene.
Thomas KH; Vankrieken L
Int J Fertil; 1989 Sep; 34 Suppl():10-21. PubMed ID: 2576249
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and biochemical results during the treatment with marvelon, a new oral contraceptive (author's transl)].
Mall-Haefeli M; Werner-Zodrow I; Huber P; Weijers MJ
Geburtshilfe Frauenheilkd; 1982 Mar; 42(3):215-22. PubMed ID: 6210600
[TBL] [Abstract][Full Text] [Related]
15. [The behavior of cytoplasmic progesterone receptors in the cycling endometrium and the effect of hormonal contraceptives].
Carol W; Jäger R; Martin P; Möller U
Zentralbl Gynakol; 1989; 111(12):793-9. PubMed ID: 2763749
[TBL] [Abstract][Full Text] [Related]
16. Ovulation-inhibiting properties of Org OD 14.
Franchimont P; Franchi F; Luisi M; Kicovic PM
Reproduccion; 1982; 6(2):61-7. PubMed ID: 6814970
[TBL] [Abstract][Full Text] [Related]
17. LH, FSH, estradiol and progesterone levels after discontinuation of hormonal contraception.
Balogh A; Ditrói F; Lampé LG
Acta Univ Palacki Olomuc Fac Med; 1981; 101():95-101. PubMed ID: 6242699
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of estradiol valerate/dienogest.
Teichmann A
Climacteric; 2003 Aug; 6 Suppl 2():17-23. PubMed ID: 14669840
[TBL] [Abstract][Full Text] [Related]
19. [The effect of oral ovulation inhibiting (mono-, bi- and triphase) contraceptives and of Continuin and Postinor on proteo- and steroid hormones].
Farkas M
Acta Pharm Hung; 1992; 62(1-2):17-30. PubMed ID: 1566635
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.
Jensen JT; Parke S; Mellinger U; Machlitt A; Fraser IS
Obstet Gynecol; 2011 Apr; 117(4):777-787. PubMed ID: 21422847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
